 |
FDA Approval Activities for this Drug
Zemplar (paricalcitol injection), Abbott NDA 20-819/S7, S11 2/24/03 3/10/03
Zemplar (paricalcitol injection), 5 mcg/mL Abbott NDA 20-819/S-003 2/2/00 2/4/00 2/4/00
Zemplar Indicated: For the prevention and treatment of secondary
hyperparathyroidism associated with chronic renal failure.
Zemplar (paricalcitol) Injection Abbott NDA 20-819 Zemplar (paricalcitol) Injection, Abbott Laboratories | Zemplar (paricalcitol) Capsules, Abbott Laboratories, Approval | Zemplar (paricalcitol) Injection, Abbott Labs, Labeling Revision | Zemplar (paricalcitol) Capsules, Abbott Laboratories, New or Modified Indication | Zemplar (paricalcitol) Capsules, Abbott Laboratories, New or Modified Indication | Zemplar (paricalcitol) Capsules, Abbott Laboratories, New or Modified Indication | Zemplar (paricalcitol) Capsules, Abbott Laboratories, Labeling Revision | Paricalcitol Capsules, TEVA Pharmaceuticals, Tentative Approval | Zemplar (paricalcitol) Injection, Abbott Laboratories, Labeling Revision | Zemplar (paricalcitol) Capsules, Abbott Laboratories, Labeling Revision | Zemplar (paricalcitol) Injection, Abbott Laboratories, Labeling Revision | Paricalcitol Injection, Sandoz Canada, Inc., Tentative Approval | Paricalcitol Injection, Sandoz, Inc., Approval | Paricalcitol Capsules, Dr. Reddy's Laboratories Ltd., Tentative Approval | Zemplar, paricalcitol, Capsule; Oral, Abbott, Manufacturing Change or Addition
^ FDA's latest approval appears at the bottom of this list. ^
|